SCHEMBL6094692

SCHEMBL6094692

[CH2]Cc1ccc(-n2nc(C)c(Cl)c2C)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
POLB P06746 1/20 0.56
SLC34A1 Q06495 2/20 0.42
MAPT P10636 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
ALDH1A1 P00352 3/20 0.41
RAB9A P51151 2/20 0.41
LMNA P02545 2/20 0.41
HTT P42858 2/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.40
NPC1 O15118 1/20 0.39
AR P10275 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
NR3C1 P04150 1/20 0.37
P2RY12 Q9H244 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6097521 0.81 KMT2A (0.57) KMT2AMEN1POLBSLC34A1MAPT
SCHEMBL12770975 0.80 POLB (0.65) KMT2AMEN1POLBSLC34A1MAPT
SCHEMBL6097009 0.80 CYP1A2 (0.40) KMT2AMEN1POLBSMN1; SMN2ALDH1A1
SCHEMBL6096261 0.79 CYP1A2 (0.56) SMN1; SMN2RAB9ALMNAHTTCYP1A2
SCHEMBL6095958 0.79 RAB9A (0.48) KMT2AMEN1SMN1; SMN2ALDH1A1RAB9A
SCHEMBL24185322 0.77 POLB (0.61) KMT2AMEN1POLBSLC34A1MAPT
SCHEMBL3571457 0.77 MEN1 (0.61) KMT2AMEN1POLBSLC34A1MAPT
SCHEMBL12770947 0.77 MEN1 (0.65) KMT2AMEN1POLBMAPTSMN1; SMN2
SCHEMBL6097652 0.76 CYP1A2 (0.50) MAPTALDH1A1LMNACYP1A2AR
SCHEMBL6206806 0.75 RAB9A (0.46) KMT2AMEN1POLBMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7001917-B2 Pyrazole compounds as anti-inflammatory and analgesic agents WARNER LAMBERT COMPANY LLC (US) 2006-02-21 US disclosed
US-20040019045-A1 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents HIRANO MISATO (JP) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019045-A1 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents PTGER1, PTGS1, PTGIR KMT2A 2815/4885MEN1 3821/4885POLB 4327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.